Primer Capital
Primer Capital is a venture capital firm based in Moscow, Russia, specializing in early-stage investments in the pharmaceutical and biotechnology sectors. Established in 2015, the firm focuses on promising projects in areas such as oncology, cardiology, rheumatology, and medical devices, among others. Primer Capital typically invests between $0.2 million and $0.5 million and also considers co-investments, collaborating with various stakeholders, including other venture capital funds, business angels, and government agencies interested in the biopharmaceutical industry. The firm benefits from a qualified team and a Scientific Advisory Board made up of experts in medical and biopharmaceutical fields, which aids in the careful selection of projects for its portfolio. Primer Capital's extensive experience and knowledge of the industry ecosystem enhance the prospects for its portfolio companies, supporting them in establishing effective partnerships and facilitating fundraising throughout their development.
Botkin.AI
Series B in 2020
Botkin.AI is a Moscow-based software platform specializing in medical image processing and analysis through artificial intelligence. Founded in 2015, the company focuses on developing advanced tools for healthcare providers to enhance the diagnosis of oncological diseases. Its platform employs deep machine learning to analyze medical images, such as radiograms, and assess the risk of tumors, particularly lung cancer, at early stages with high accuracy. By streamlining the analysis of clinical data, Botkin.AI enables radiologists to diagnose tumors more effectively and efficiently, improving patient outcomes without compromising the quality of medical conclusions.
Botkin.AI
Seed Round in 2017
Botkin.AI is a Moscow-based software platform specializing in medical image processing and analysis through artificial intelligence. Founded in 2015, the company focuses on developing advanced tools for healthcare providers to enhance the diagnosis of oncological diseases. Its platform employs deep machine learning to analyze medical images, such as radiograms, and assess the risk of tumors, particularly lung cancer, at early stages with high accuracy. By streamlining the analysis of clinical data, Botkin.AI enables radiologists to diagnose tumors more effectively and efficiently, improving patient outcomes without compromising the quality of medical conclusions.
Data MATRIX
Series A in 2016
Data MATRIX Ltd. is a data management and biostatistics company based in Saint Petersburg, Russia, founded in 2014. It specializes in providing a comprehensive range of services for clinical trials, including its cloud-based electronic data capture platform, Matrix EDC, which supports various study formats. The company offers tools for patient randomization with Matrix IWRS and clinical trial management through Matrix CTMS. Data MATRIX also emphasizes data verification through both automated and manual methods, ensuring compliance with international and local regulations regarding personal data processing. Additionally, the company provides electronic patient-reported outcomes (ePRO) solutions to enhance data collection accuracy. With a focus on integrating artificial intelligence into its operations, Data MATRIX develops tools that facilitate data cleaning, curation, and validation to support clinical research initiatives effectively.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.